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P<0.05 for all comparisons TAXUS vs Control except TLR in DM insulin group (p=0.32)
Conclusions. TLR was significantly improved in all diabetics, diabetics on oral meds and 
trended towards improvement in the insulin-requiring diabetic group. Significant benefits 
of the paclitaxel-eluting TAXUS stent for QCA parameters (binary restenosis and late 
loss) compared with control were demonstrated in all three diabetic groups, including 
those requiring insulin. The beneficial effect of the TAXUS stent seen in the overall study 
population is preserved in the high-risk diabetic groups.
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1059-6 The Multicenter Evaluation of the Everolimus-Eluting 
Stent for Inhibition of Neointimal Hyperplasia: Results 
of the Pooled FUTURE I and II Trials
Ricardo A. Costa, Alexandra J. Lansky, Roxana Mehran, Yoshihiro Tsuchiya, Ecaterina 
Cristea, Yeal Gilutz, Maria Coral, Manuela Negoita, Ramona Pop, Michael Rink, Ralf 
Muller, George Techen, Eberhard Grube, Cardiovascular Research Foundation, New 
York, NY, Heart Center, Siegburg, Germany
The single center first-in-man randomized FUTURE I trial, demonstrated safety and
effectiveness of the everolimus-eluting stent (EES) to inhibit neointimal proliferation in de
novo coronary lesions compared to the bare metal stent (BMS). The FUTURE II trial was
a larger multicenter randomized trial of the EES, with inclusion of more complex patients,
such as diabetics. We report the 6-month results of the FUTURE I + II trials. Methods
and Results: 106 patients with 107 de novo coronary lesions were randomized to EES
(n=48) vs. BMS (n=58). Baseline clinical and angiographic characteristics were similar in
both groups, with 16% diabetics and lesion length of 10.42±3.37mm. Final and 6-month
angiographic results are shown in the Table. Conclusions: Patients treated with the EES
in the FUTURE I and II trials, had a dramatic decrease in late loss both in-stent (85.9%)
and in-segment (66%) compared to the bare metal stent group at 6 months. Concor-
dantly, restenosis was also significantly reduced with EES both within the stent and the
treated segment.
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1059-7 Impact of Late Loss on Clinical, Angiographic and 
Intravascular Ultrasound Outcomes in the TAXUS IV 
Trial
Stephen Ellis, Jeffrey J. Popma, Neil Weissman, Mark Turco, Ronald Caputo, Patrick 
Bergin, Joel Greenberg, Albert Raizner, Joerg Koglin, Mary E. Russell, Gregg W. Stone, 
The TAXUS IV Investigators, Brigham and Women's Hospital, Boston, MA, Cleveland 
Clinic Foundation, Cleveland, OH
Background. The optimal amount of late loss for drug-eluting stents has yet to be deter-
mined, but theoretically should be a balance between positive and negative remodeling.
The relationship between angiographic late loss and target lesion revascularization
(TLR), binary restenosis, and neointimal volume has also not been studied with drug-
eluting stents.
Methods. TAXUS IV was a prospective, randomized, double-blind study in which 1,314
patients at 73 US sites were randomized to the polymer-based paclitaxel slow release
TAXUS Express stent (n=662) or bare metal Express stent (n=652).
Results. As shown in the table, the 9-month rates of TLR, angiographic restenosis, and
IVUS neointimal volume were markedly reduced with the TAXUS stent compared to con-
trol. 
Regression analysis showed that TLR and binary restenosis were correlated with late 
loss. At late loss levels of less than approximately 0.6 mm the likelihoods of TLR and 
binary restenosis were between 0% and 1%. TLR and binary restenosis occurred in 50% 
of patients when late loss was ~1.6 mm and ~1.2 respectively.
Conclusions. Angiographic late loss levels <0.6 mm are associated with a low likelihood 
of clinical TLR, angiographic restenosis, and neointimal obstruction. Late loss at 9 
months by baseline RVD, lesion length and other variables will be further explored.
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1059-8 Coronary Plaque Regression by Simvastatin Is 
Associated With Reduction in Vessel Volume: A Three-
Dimensional Intravascular Ultrasound Study
Lisette Okkels Jensen, Per Thayssen, Knud Erik Pedersen, Torben Haghfelt, Odense 
University Hospital, Odense, Denmark
Background: In the early stage of the coronary atherosclerotic plaques, pathophysiolog-
ical studies have demonstrated that the vessel wall may remodel and accumulate plaque
material without causing morphologically detectable changes in lumen diameter. The aim
of the study was to investigate the effect of lipid-lowering by simvastatin on coronary ath-
erosclerotic plaques as well as changes in the volumes of plaque, lumen and vessel.
Methods: In 40 male patients with hypercholesterolemia and a non significant coronary
artery lesion 3D IVUS during ECG-triggered pullback was performed at baseline, after 3
months on a lipid lowering diet and after another12 months on diet plus simvastatin 40
mg/day. All segments contained at least one side branch used for the correct matching of
the site of measurement at follow-up.
Results: Mean length of the analysed atherosclerotic segments was 5.9 ± 3.3 mm.
Twenty-three left anterior descending coronary artery segments, 6 circumflex segment
and 11 right coronary artery segments were analysed. Mean minimal lumen diameter
was 2.6 ± 0.6 mm, maximum plaque burden was 62.1 ± 13.6 % and mean diameter of
reference segments were 3.5 ± 0.6 mm. After 12 months on simvastatin the reductions in
total cholesterol of 31.0% (6.1 ± 0.8 vs. 4.2 ± 0.7, p<0.001) and LDL cholesterol of 42.6%
(4.0 ± 0.8 vs. 2.2 ± 0.6, p<0.001) were significant.
After 12 months on simvastatin a significant reduction in plaque volume of 6.9%
(p<0.001) and vessel volume of 3.6% (p<0.001) were observed without any concomitant
change in lumen volume. There was a significant linear correlation between the percent-
age change in volume for plaque and vessel (r=0.652, p<0.001), lumen and vessel
(r=0.737, p<0.001), while there was no correlation between plaque and lumen (r=0.027,
p=0.869) after 12 months simvastatin therapy.
Conclusion: Lipid-lowering therapy with simvastatin for 12 months is associated with a
significant plaque regression in coronary arteries measured as reduction in plaque and
vessel volumes without any concomitant change in lumen volume. An explanation for this
may be that remodeling takes place in the vessel wall only.
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1059-9 Platelet P-Selectin and Plasma Levels of Circulating 
Cytokines in Young Patients With Mild Arterial 
Hypertension
Christian Stumpf, Jelena Jukic, Atilla Yilmaz, Stefan John, Dorette Raaz, Roland E. 
Schmieder, Werner G. Daniel, Christoph D. Garlichs, University of Erlangen, Erlangen, 
Germany, University of Erlangen, Erlangen, Germany
The role of inflammatory mechanisms for the development of vascular damage in athero-
sclerosis (AS) has been increasingly acknowledged during recent years. In this setting
animal models have revealed the important role of platelet P-selectin on progression of
AS. Although these observations have stimulated research on the role of vascular inflam-
mation in patients with arterial hypertension (AH), the overall contribution of inflammation
in AH, one of the leading cardiovascular risk factors, is far from being clear. Therefore,
the present pilot study was designed to examine the role of platelet P-selectin and vari-
ous inflammatory mediators in an early stage of AH in young patients without signs of tar-
get organ damage. 
15 patients with mild AH (33.8+7.3 years, systolic blood pressure [SBP] 143.8+10.5
mmHg, diastolic blood pressure [DBP] 88.2+11.1 mmHg, mean arterial pressure [MAP]
106.6+10.4 mmHg) and 15 healthy normotensive controls (31.7+10.6 years) were exam-
ined. Blood was drawn from a peripheral vein. Platelet P-selectin was analysed by flow
cytometry. MCP-1, hsCRP, interleukin (IL)-6, TNFα, and IL-10 levels were measured via
EIA. 
AH patients showed significantly enhanced expression of platelet P-selectin (17.2+5.4 vs
10.6+4.2 mean fluorescence intensity [MFI], p<0.001). P-selectin expression positively
correlated with MAP (r=0.58, p<0.001). Furthermore AH patients had significantly
enhanced plasma levels of hsCRP (2.7+3.8 vs 0.6+0.9 mg/L, p<0.01), IL-6 (1.4+0.7 vs
0.6+0.3 pg/mL, p<0.001), TNFα (2.8+0.7 vs. 2.4+0.4 pg/mL, p<0.05) and MCP-1
(291.3+100.7 vs 214.3+8.3 pg/mL, p<0.05). IL-6 levels positively correlated with hsCRP
levels (r=0.80, p<0.001) and MAP (r=0.68, p<0.01).
This pilot study demonstrates that in an early state of AH inflammatory mechanisms are
already activated. Beside proinflammatory cytokines, platelets seem to play an important
role in mediating inflammation in the progression of AH. It is possible that these mecha-
nisms play a pathogenic role in mediating target organ injury. However further investiga-
tions have to clarify the role of an early anti-inflammatory therapy in patients with mild to
moderate AH to alleviate hypertensive target organ damage.
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1059-10 Antibodies to Infectious Pathogen Are Associated With 
Hypertension
Jianhui Zhu, Arshed Quyyumi, Daniel Canos, Julian Halcox, Stephen Epstein, 
Washington Hospital Center, Washington, DC
Background: Infection has been implicated as contributing to the pathogenesis of athero-
sclerosis. Given the recognized relationship between hypertension (HTN) and athero-
sclerosis, this study determined whether antibodies to infectious pathogens are
associated with HTN, and whether this association is, in part, through infection-induced
inflammation. Methods: We evaluated 415 patients (62% men, mean age 57 years) for
Quantitative Coronary Angiography
Variable (Number of Lesions) EES (N=49) BMS (N=58) P-value
Reference Diameter, mm 3.01±0.42 2.97±0.51 0.6
Final MLD, mm 2.98±0.38 2.88±0.38 0.2
Acute Gain, mm 1.90±0.43 1.83±0.44 0.5
FU Stent MLD, mm 2.86±0.41 2.04±0.68 <0.0001
FU Segment MLD, mm 2.32±0.52 1.77±0.62 <0.0001
Stent Late Loss, mm 0.12±0.25 0.85±0.53 <0.0001
Segment Late Loss, mm 0.17±0.36 0.50±0.51 0.0005
Stent Restenosis, % 0.0% 17.0% 0.006
Segment Restenosis, % 4.3% 27.7% 0.002
TLR (%) Binary restenosis
(%, in-stent)
% in-stent net volume 
obstruction
Late loss (mm)
TAXUS 3.0 5.5 12.2 0.39 ±0.50
Control 11.3 24.4 29.4 0.92 ±0.58
